Isaac Barchas Sells 101,050 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 101,050 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00. Following the sale, the director owned 308,504 shares in the company, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.

Immunome Trading Up 9.9%

NASDAQ:IMNM traded up $2.12 during mid-day trading on Thursday, hitting $23.61. The stock had a trading volume of 1,869,014 shares, compared to its average volume of 1,683,587. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65. The company has a 50 day simple moving average of $20.96 and a 200-day simple moving average of $21.78. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -9.92 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently added to or reduced their stakes in IMNM. T. Rowe Price Investment Management Inc. boosted its stake in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the period. Vanguard Group Inc. raised its position in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the period. Primecap Management Co. CA raised its stake in Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the period. State Street Corp boosted its position in shares of Immunome by 37.9% during the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after acquiring an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after acquiring an additional 2,823,144 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on IMNM shares. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Truist Financial lifted their price objective on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Stephens decreased their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Craig Hallum lifted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Leerink Partners lowered their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.